Preclinical Proof of Concept for a Virtual Biotech: Advancing Transcend's Neuropsychiatric Pipeline

Transcend Therapeutics, a virtual biotech with no in-house lab, needed a preclinical in vivo CRO that combined large-CRO rigor with boutique flexibility. Across 20 experiments, Melior Discovery designed and executed preclinical proof of concept studies using 7 translatable in vivo models—5 established assays and 2 bespoke assays custom-built from the literature—to rigorously evaluate Transcend’s neuropsychiatric candidates. Melior delivered personalized study designs and applied deep domain expertise to guide interpretation of study outputs, ultimately producing faster timelines, high-quality reproducible data, and a trusted long-term research partnership.  Transcend has since been acquired by Otsuka America, Inc. to advance their portfolio of next-generation treatments for serious neuropsychiatric conditions.

Transcend Therapeutics is a biotech company developing rapid-acting treatments for neuropsychiatric disorders. As a virtual organization without an in-house lab, Transcend needed a reliable partner to execute the complex, translatable in vivo behavioral studies its drug development pipeline depended on.

Developing novel treatments for neuropsychiatric disorders requires numerous and complex animal studies, so finding the right proof-of-concept CRO for their discovery program was a challenge. Large CROs often lacked the flexibility to build tailored, bespoke study designs around custom behavioral models, while smaller vendors didn’t always have the scientific acumen or domain expertise needed to ensure reliable results.  Transcend needed a CRO that could serve as an extension of its research team: executing studies accurately, troubleshooting challenges in real time, and adapting study designs to meet evolving research goals.

Melior’s expertise in translatable behavioral in vivo models, its ability to rigorously establish preclinical proof of concept studies, and its responsive, scientist-to-scientist approach made it the ideal partner to generate the data Transcend needed to move their pipeline forward with confidence.

For a virtual biotech, every preclinical decision hinges on data generated somewhere else. Transcend had no lab of its own, which meant the quality of its neuropsychiatric pipeline was only as strong as the partners running its in vivo studies in behavioral pharmacology; that bar is unusually high. Subtle differences in model selection, protocol design, and animal handling can determine whether a candidate looks promising or fails to separate from control, so the cost of an unreliable partner isn’t just a wasted study; it’s a misread on an entire asset.

That raised the stakes on a familiar trade-off. The CROs with the deepest scientific benches were often too rigid to explore the custom behavioral models Transcend’s programs called for, while the more nimble vendors frequently couldn’t guarantee the rigor needed to trust a result or help guide the interpretation. Transcend needed a partner scientifically fluent enough to build and validate translatable in vivo models from the literature, and flexible enough to adapt them as programs evolved.

Just as important was how that partner would work. Without in-house scientists to catch problems or pressure-test an in vivo study design, Transcend needed a proof of concept CRO willing to think alongside its team, flagging confounds before they compromised a dataset and helping guide the interpretation of what the results actually meant for the pipeline.

What Transcend needed in a partner:

• Translatable in vivo models with clinical relevance
• Rigorously established preclinical proof of concept capabilities
• Bespoke expertise in in vivo study design and behavioral models 
• Domain expertise to help guide study output interpretation for neuropsychiatric candidates
• Flexibility to design and build custom models, not just run predefined protocols
• Fast, reliable timelines to support getting results from proof of concept studies right away 
• Collaborative approach with in-house scientific experts to support troubleshooting and problem-solving, delivering a sense of shared ownership

To bridge the gap between scientific vision and execution, Melior became an integral research partner for Transcend, providing the expertise, flexibility, and collaboration needed to run complex in vivo preclinical proof of concept studies. Across 20 experiments, Melior deployed 7 preclinical models: 5 established assays tailored to Transcend’s pipeline and 2 custom-built models developed from the literature, all used to evaluate candidate compounds.

What set Melior apart from a conventional service provider was its proactive approach to in vivo study design. Rather than simply running predefined protocols, Melior worked closely with Transcend to troubleshoot challenges and optimize workflows, often surfacing the variables most vendors overlook. That blend of scientific rigor, adaptability, and hands-on collaboration gave Transcend the confidence to keep advancing its pipeline.

How Melior delivered:

• Served as a seamless extension of Transcend’s research capabilities, executing critical in vivo preclinical proof of concept studies
• Proactively identified experimental risks and adjusted designs to improve data quality and reproducibility
• Built and validated 2 custom preclinical proof of concept models from the literature to match Transcend’s specific research goals
• Facilitated a collaborative, scientist-to-scientist process with a consistent study director across projects
• Generated reproducible data that enabled Transcend to drive its assets through the drug development pipeline

Partnering with Melior as its preclinical proof of concept CRO, Transcend generated the high-quality, reproducible data needed to advance its neuropsychiatric drug pipeline. Most studies were completed within a month, and timelines kept improving over the course of the partnership, so Melior’s rapid yet scientifically sound work consistently kept Transcend’s research on track. That combination of speed and reliability delivered:

• Reproducible, high-quality data that supported timely decisions across Transcend’s drug development program
• Faster study timelines, with most experiments completed within a month and improving as the partnership matured
• Validated custom and established preclinical proof of concept models tailored to Transcend’s pipeline

Transcend has since been acquired by Otsuka America, Inc. to advance its portfolio of next-generation treatments for serious neuropsychiatric conditions.